Maat Pharma SA
PAR:MAAT
Intrinsic Value
The intrinsic value of one MAAT stock under the Base Case scenario is 1.9 EUR. Compared to the current market price of 8 EUR, Maat Pharma SA is Overvalued by 76%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Maat Pharma SA
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
Fundamental Analysis
Revenue & Expenses Breakdown
Maat Pharma SA
Balance Sheet Decomposition
Maat Pharma SA
Current Assets | 40.6m |
Cash & Short-Term Investments | 32.1m |
Receivables | 7.1m |
Other Current Assets | 1.5m |
Non-Current Assets | 10.3m |
Long-Term Investments | 200k |
PP&E | 8.5m |
Intangibles | 1.3m |
Other Non-Current Assets | 238k |
Earnings Waterfall
Maat Pharma SA
Revenue
|
2.6m
EUR
|
Cost of Revenue
|
-826k
EUR
|
Gross Profit
|
1.7m
EUR
|
Operating Expenses
|
-25.9m
EUR
|
Operating Income
|
-24.2m
EUR
|
Other Expenses
|
27k
EUR
|
Net Income
|
-24.1m
EUR
|
MAAT Profitability Score
Profitability Due Diligence
Maat Pharma SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Maat Pharma SA's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
MAAT Solvency Score
Solvency Due Diligence
Maat Pharma SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Maat Pharma SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MAAT Price Targets Summary
Maat Pharma SA
According to Wall Street analysts, the average 1-year price target for MAAT is 16.49 EUR with a low forecast of 13.94 EUR and a high forecast of 22.05 EUR.
Dividends
Current shareholder yield for MAAT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one MAAT stock under the Base Case scenario is 1.9 EUR.
Compared to the current market price of 8 EUR, Maat Pharma SA is Overvalued by 76%.